Previous 10 | Next 10 |
home / stock / hmtxf / hmtxf news
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. CALGARY, Alberta, Jan. 02, 2020 (GLOBE NEWSWIRE) -- Hemostemix Inc. (“ Hemostemix ” or the “ Company ”) (TSX VENTURE: HEM; OTC: HMTXF), announces the Company will...
CALGARY, Alberta, Dec. 11, 2019 (GLOBE NEWSWIRE) -- Hemostemix Inc. (“ Hemostemix ” or the “ Company ”) (TSX VENTURE: HEM; OTC: HMTXF) is pleased to announce the appointment of David Wood to the position of Chairman, Bryson Goodwin to the position of Chief Execut...
CALGARY, Alberta, Dec. 02, 2019 (GLOBE NEWSWIRE) -- Hemostemix Inc. (“ Hemostemix ” or the “ Company ”) (TSX VENTURE: HEM; OTC: HMTXF), a biotechnology company focused on developing and commercializing innovative blood-derived stem cell therapies for medical cond...
CALGARY, Alberta, Nov. 29, 2019 (GLOBE NEWSWIRE) -- Hemostemix Inc. (“ Hemostemix ” or the “ Company ”) (TSX VENTURE: HEM; OTCQB: HMTXF), a biotechnology company focused on developing and commercializing innovative blood-derived stem cell therapies for medical co...
CALGARY, Alberta, Nov. 22, 2019 (GLOBE NEWSWIRE) -- Hemostemix Inc. (“ Hemostemix ” or the “ Company ”) (TSX VENTURE: HEM; OTCQB: HMTXF), a biotechnology company focused on developing and commercializing innovative blood-derived stem cell therapies for medical co...
CALGARY, Alberta, Oct. 31, 2019 (GLOBE NEWSWIRE) -- Hemostemix Inc. (“ Hemostemix ” or the “ Company ”) (TSX VENTURE: HEM; OTCQB: HMTXF), is a biotechnology company developing and commercializing blood-derived stem cell therapies for unmet medical conditions, ann...
CALGARY, Alberta, Oct. 21, 2019 (GLOBE NEWSWIRE) -- Hemostemix Inc. (“ Hemostemix ” or the “ Company ”) (TSX VENTURE: HEM; OTCQB: HMTXF), a biotechnology company developing and commercializing blood-derived stem cell therapies for unmet medical conditions, is ple...
CALGARY, Alberta, Oct. 17, 2019 (GLOBE NEWSWIRE) -- Hemostemix Inc. (“ Hemostemix ” or the “ Company ”) (TSX VENTURE: HEM; OTCQB: HMTXF), a biotechnology company focused on developing and commercializing innovative blood-derived stem cell therapies for medical co...
NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES CALGARY, Alberta, Aug. 01, 2019 (GLOBE NEWSWIRE) -- Hemostemix Inc. (“ Hemostemix ” or the “ Company ”) (TSX VENTURE: HEM; OTCQB: HMTXF), a biotechnology company focused on...
CALGARY, Alberta, July 11, 2019 (GLOBE NEWSWIRE) -- Hemostemix Inc. (“ Hemostemix ” or the “ Company ”) (TSX VENTURE: HEM; OTCQB: HMTXF), a biotechnology company focused on developing and commercializing innovative blood-derived stem cell therapies for medical co...
News, Short Squeeze, Breakout and More Instantly...
Calgary, Alberta--(Newsfile Corp. - June 11, 2024) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is pleased to announce it was notified by the World Intellectual Property Organization that it was granted the trademark Your Fountain of Youth by the Swiss Trademark Office. "In four h...
2024-06-03 13:23:23 ET In a press release this morning, %Hemostemix Inc. (TSXV: $HEM) (OTC: $HMTXF) announced it had signed a Letter of Intent ("LOI") with CytoImmune Therapeutics. The LOI will re-establish production of ACP-01 ("ACP") in CytoImmune's state-of-the-art clinical cell manu...
Calgary, Alberta--(Newsfile Corp. - June 3, 2024) - Hemostemix Inc. (TSXV: HEM) (OTC Pink: HMTXF) (FSE: 2VF0) is pleased to announce it has signed a Letter of Intent ("LOI") with CytoImmune Therapuetics ("CytoImmune") to re-establish production of ACP-01 ("ACP") in CytoImmune's state-of-the-art c...